PHOTOCURE REGAINS WORLDWIDE RIGHTS OF HEXVIX
HIGHLIGHTS · Photocure has reached an agreement with Ipsen to regain rights for the sales and marketing of Hexvix[®] in Europe · The transaction is expected to be EBITDA accretive from FY 2021 · Ipsen achieved Hexvix 2019 sales of EUR 18.7 million and Photocure sees significant growth opportunities in EuropeOslo, Norway, 27 April 2020: Photocure ASA (Photocure, PHO: OSE) has reached an agreement with Ipsen Pharma SAS (Ipsen) on key terms for the return of Hexvix sales, marketing and distribution rights in Europe and other markets currently controlled by Ipsen. With taking direct